Peroxiredoxin 3 levels regulate a mitochondrial redox setpoint in malignant mesothelioma cells

被引:35
作者
Cunniff, Brian [1 ]
Wozniak, Alexandra N. [2 ]
Sweeney, Patrick [2 ]
DeCosta, Kendra [2 ]
Heintz, Nicholas H. [2 ]
机构
[1] Univ Utah, Dept Biochem, Salt Lake City, UT USA
[2] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA
来源
REDOX BIOLOGY | 2014年 / 3卷
关键词
Peroxiredoxin; 3; Mitochondrial structure; Cell cycle; Oxidative stress; CYCLE PROGRESSION; HYDROGEN-PEROXIDE; SULFINIC ACID; FISSION; TRANSITIONS; EXPRESSION; CYSTEINE; STATE; PHOSPHORYLATION; DEGRADATION;
D O I
10.1016/j.redox.2014.11.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Peroxiredoxin 3 (PRX3), a typical 2-Cys peroxiredoxin located exclusively in the mitochondrial matrix, is the principal peroxidase responsible for metabolizing mitochondrial hydrogen peroxide, a byproduct of cellular respiration originating from the mitochondrial electron transport chain. Mitochondrial oxidants are produced in excess in cancer cells due to oncogenic transformation and metabolic reorganization, and signals through FOXM1 and other redox-responsive factors to support a hyper-proliferative state. Over-expression of PRX3 in cancer cells has been shown to counteract oncogene-induced senescence and support tumor cell growth and survival making PRX3 a credible therapeutic target. Using malignant mesothelioma (MM) cells stably expressing shRNAs to PRX3 we show that decreased expression of PRX3 alters mitochondrial structure, function and cell cycle kinetics. As compared to control cells, knockdown of PRX3 expression increased mitochondrial membrane potential, basal ATP production, oxygen consumption and extracellular acidification rates. shPRX3 MM cells failed to progress through the cell cycle compared to wild type controls, with increased numbers of cells in G2/M phase. Diminished PRX3 expression also induced mitochondrial hyperfusion similar to the DRP1 inhibitor mdivi-1. Cell cycle progression and changes in mitochondrial networking were rescued by transient expression of either catalase or mitochondrial-targeted catalase, indicating high levels of hydrogen peroxide contribute to perturbations in mitochondrial structure and function in shPRX3 MM cells. Our results indicate that PRX3 levels establish a redox set point that permits MM cells to thrive in response to increased levels of mROS, and that perturbing the redox status governed by PRX3 impairs proliferation by altering cell cycle-dependent dynamics between mitochondrial networking and energy metabolism. (C) 2014 The Authors. Published by Elsevier B.V.
引用
收藏
页码:79 / 87
页数:9
相关论文
共 32 条
  • [1] Peroxiredoxin 3 Is a Redox-Dependent Target of Thiostrepton in Malignant Mesothelioma Cells
    Newick, Kheng
    Cunniff, Brian
    Preston, Kelsey
    Held, Paul
    Arbiser, Jack
    Pass, Harvey
    Mossman, Brooke
    Shukla, Arti
    Heintz, Nicholas
    PLOS ONE, 2012, 7 (06):
  • [2] Disabling Mitochondrial Peroxide Metabolism via Combinatorial Targeting of Peroxiredoxin 3 as an Effective Therapeutic Approach for Malignant Mesothelioma
    Cunniff, Brian
    Newick, Kheng
    Nelson, Kimberly J.
    Wozniak, Alexandra N.
    Beuschel, Stacie
    Leavitt, Bruce
    Bhave, Anant
    Butnor, Kelly
    Koenig, Andreas
    Chouchani, Edward T.
    James, Andrew M.
    Haynes, Alexina C.
    Lowther, W. Todd
    Murphy, Michael P.
    Shukla, Arti
    Heintz, Nicholas H.
    PLOS ONE, 2015, 10 (05):
  • [3] Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cells
    Cunniff, Brian
    Benson, Kira
    Stumpff, Jason
    Newick, Kheng
    Held, Paul
    Taatjes, Douglas
    Joseph, Joy
    Kalyanaraman, Balaraman
    Heintz, Nicholas H.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2013, 228 (04) : 835 - 845
  • [4] Mitochondrial peroxiredoxin 3 is rapidly oxidized in cells treated
    Brown, Kristin K.
    Eriksson, Sofi E.
    Arner, Elias S. J.
    Hampton, Mark B.
    FREE RADICAL BIOLOGY AND MEDICINE, 2008, 45 (04) : 494 - 502
  • [5] Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma
    Murakami, Aki
    Tabata, Chiharu
    Tabata, Rie
    Okuwa, Hisaya
    Nakano, Takashi
    ONCOLOGY LETTERS, 2012, 3 (03) : 581 - 585
  • [6] Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP+
    De Simoni, Stephanie
    Goemaere, Julie
    Knoops, Bernard
    NEUROSCIENCE LETTERS, 2008, 433 (03) : 219 - 224
  • [7] Activation of platelet-derived growth factor receptors regulate connective tissue growth factor protein levels via the AKT pathway in malignant mesothelioma cells
    Suehiro, Tomoya
    Ahmad, Khoja Mouhand
    Hoang, Nguyen Truong Duc
    Xu, Bingwen
    Komatsu, Honoka
    Kurachi, Komei
    Nikawa, Hiroki
    Mine, Yuichi
    Matsuki, Tohru
    Asano, Katsura
    Fujii, Makiko
    JOURNAL OF BIOCHEMISTRY, 2024, 176 (06) : 460 - 471
  • [8] Activation of the PI3K-AKT pathway in human malignant mesothelioma cells
    Suzuki, Yutaro
    Murakami, Hideki
    Kawaguchi, Koji
    Taniguchi, Tetsuo
    Fujii, Makiko
    Shinjo, Keiko
    Kondo, Yutaka
    Osada, Hirotaka
    Shimokata, Kaoru
    Horio, Yoshitsugu
    Hasegawa, Yoshinori
    Hida, Toyoaki
    Sekido, Yoshitaka
    MOLECULAR MEDICINE REPORTS, 2009, 2 (02) : 181 - 188
  • [9] Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo
    Miyoshi, Seigo
    Hamada, Hironobu
    Hamaguchi, Naohiko
    Kato, Aki
    Katayama, Hitoshi
    Irifune, Kazunori
    Ito, Ryoji
    Miyazaki, Tatsuhiko
    Okura, Takafumi
    Higaki, Jitsuo
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 41 (02) : 449 - 456
  • [10] Latent TGF-β binding proteins (LTBPs) 1 and 3 differentially regulate transforming growth factor-β activity in malignant mesothelioma
    Vehvilainen, Piia
    Koli, Katri
    Myllarniemi, Marjukka
    Lindholm, Pamela
    Soini, Ylermi
    Salmenkivi, Kaisa
    Kinnula, Vuokko L.
    Keski-Oja, Jorma
    HUMAN PATHOLOGY, 2011, 42 (02) : 269 - 278